		ADVERSE EVENT REPORTING FORM (In Confidence)	Scipca					
Α.	PATIENT INFORMATION 1. Patient Initials :	3. Sex : M F 4. Age at time of event : years OR 5. Date of Birth: (dd/mm/yyyy)	6. Weight : Kg					
В.	ADVERSE EVENT I. Do you consider the adverse event to be serious? Yes No 2. If yes, please indicate why the adverse event is considered to be serious : (Check all that apply) Congenital anomaly / Death							
	 If the adverse event is not serious, Date of onset of event:	nd hospital discharge summaries as required) s, indicate intensity of the adverse reaction : Mild Moderate Severe (dd/mm/yyyy) 5. If event stopped, date: (dd/mm/yyyy) (hh/mm) Time (if available) (hh/mm) n of reaction(s), including body site and severity as well as description of signs and symptoms. specific diagnosis for the reaction)						
	7. Information on recovery and any Other:	Not recovered Fatal	Recovered with sequelae					
	 8. Setting where event occurred: Hospital Out-Patient 9. Relevant tests / laboratory data, in 							
	10. Other relevant history, including pre hepatic / renal dysfunction, etc.	eexisting medical conditions: (e.g. allergies, race, pregnancy, smoking a	and alcohol use,					
	11. Treatment of adverse event :							

SUSPECT MEDICATI	ON(S)						
1. Generic Name	2. Brand Name	3. Dosage form & labeled strength	4. Lot No./Batch No.	5. Expiry Date	6. Manufacturer		
# 1							
# 2							
# 3							
# 4							
7. Daily Dose (Specify units - mg, ml, mg/kg	8. Frequency g)	8. Frequency 9. Route of administration		11. Therapy dates (if unknown, give duration) Start End			
# 1				(dd/mm/yyyy) Therapy duration:	(days)		
# 2				(dd/mm/yyyy) Therapy duration:	(days)		
# 3				(dd/mm/yyyy) Therapy duration:	(days)		
# 4				(dd/mm/yyyy) Therapy duration:			
L 12. Event abated afte	er use stopped or d	ose reduced :	13. Event reappeared a		(uuys)		
#1 Yes No	Not app	olicable	Yes No	Not applicabl	e		
15. Concomitant medic	al products and ther osage form and	Daily dose Ro	nedication and herbal remeduation for	dies : (exclude those us Starting	Stopping		
#1	abeled strength _{e.}	g. mg, ml, mg/kg) admir	nistration use of the drug	date	date		
# 2				(dd/mm/yyyy)	(dd/mm/yyyy)		
# 3				(dd/mm/yyyy)	(dd/mm/yyyy)		
# 4				(dd/mm/yyyy)	(dd/mm/yyyy)		
D. REPORTER 1. Name and address							
Tel. No. (With STD Coo 2. Date of this Report			essional? Yes No	4. Occupation _			
5. Also reported to: Regulatory authority Distributor No one else 6. Report Type : Initial Follow-up							
Signature							
Please send this form Corporate Pharmacovi Ipca Laboratories Ltd 142-AB, Kandivli Indus T:+91 22 6647 4105,	gilance Cell • trial Estate, Kandivli	(West), Mumbai 400 067 ince.mumbai@ipca.com	', India				
If any additional d							